Provided by Tiger Trade Technology Pte. Ltd.

Annexon, Inc.

5.07
-0.1100-2.12%
Post-market: 5.110.0400+0.79%19:49 EDT
Volume:1.43M
Turnover:7.31M
Market Cap:963.30M
PE:-4.50
High:5.28
Open:5.24
Low:5.02
Close:5.18
52wk High:7.18
52wk Low:2.03
Shares:190.00M
Float Shares:164.00M
Volume Ratio:0.51
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1271
EPS(LYR):-1.3445
ROE:-105.26%
ROA:-51.54%
PB:5.18
PE(LYR):-3.77

Loading ...

Annexon Reports Inducement Grants to New Employees Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 18

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 18

Annexon participates in a conference call with JPMorgan

TIPRANKS
·
Aug 17

Jasper Therapeutics Q2 Loss Per Share Beats Estimates, Raises $132 Mln

Reuters
·
Aug 14

ProMIS Neurosciences Q2 Net Loss Widens

Reuters
·
Aug 14

Annexon Raised to Market Perform from Market Underperform by Citizens

Dow Jones
·
Aug 13

Annexon Files Form 3 as Director Mark S. Blumenkranz Reports no Beneficial Ownership

Reuters
·
Aug 13

Annexon, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Annexon: Strategic Phase 3 Trial Flexibility Supports Buy Rating and Unchanged $25 Price Target

TIPRANKS
·
Aug 12

Annexon Falls on Bigger-than-Expected Quarterly Loss

Reuters
·
Aug 12

Annexon Shares Fall 6.4% Premarket After Wider-than-Expected Q2 Net Loss

THOMSON REUTERS
·
Aug 12

Annexon Q2 FY26 Net Loss Widens to $55.35 Million

Reuters
·
Aug 12

Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate

Benzinga Earnings
·
Aug 12

Annexon Biosciences Q2 Net Loss Widens, Cash Runway Extended

Reuters
·
Aug 12

Earnings Flash (ANNX) Annexon Posts Q2 Loss $0.28 a Share, vs. FactSet Est of $0.23 Loss

MT Newswires Live
·
Aug 12

Annexon Biosciences Q2 Operating Expenses USD 57.227 Million

THOMSON REUTERS
·
Aug 12

Annexon Biosciences Q2 Basic EPS USD -0.28

THOMSON REUTERS
·
Aug 12

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

THOMSON REUTERS
·
Aug 12

Annexon Adds Month 24 Dual Primary Endpoint to Phase 3 Archer II Trial of Vonaprument in Geographic Atrophy

Reuters
·
Aug 12